These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 23792118

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, Marchetti C, Minarini A, Cilli M, Emionite L, Di Paolo D, Brignole C, Piaggio F, Perri P, Tumiatti V, Pistoia V, Pagnan G, Ponzoni M.
    J Control Release; 2015 Aug 10; 211():44-52. PubMed ID: 26031842
    [Abstract] [Full Text] [Related]

  • 3. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.
    Cancer Res; 2003 Nov 01; 63(21):7400-9. PubMed ID: 14612539
    [Abstract] [Full Text] [Related]

  • 4. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
    Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP.
    Clin Cancer Res; 2007 May 15; 13(10):3079-86. PubMed ID: 17505011
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
    Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Montaldo PG, Gambini C, Allen TM, Bogenmann E, Ponzoni M.
    Int J Cancer; 2003 May 01; 104(5):559-67. PubMed ID: 12594810
    [Abstract] [Full Text] [Related]

  • 6. Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
    Carosio R, Pistoia V, Orienti I, Formelli F, Cavadini E, Mangraviti S, Montaldo PG, Ognio E, Emionite L, Zuccari G.
    J Pharm Pharmacol; 2012 Feb 01; 64(2):228-36. PubMed ID: 22221098
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F.
    J Control Release; 2010 Jul 01; 145(1):66-73. PubMed ID: 20346382
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
    Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M.
    Cancer Res; 2006 Oct 15; 66(20):10073-82. PubMed ID: 17047071
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of neuroblastoma-induced angiogenesis by fenretinide.
    Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, Montaldo PG, De Falco G, Caruso A, Vacca A, Ponzoni M.
    Int J Cancer; 2001 Nov 01; 94(3):314-21. PubMed ID: 11745408
    [Abstract] [Full Text] [Related]

  • 15. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
    Villani MG, Appierto V, Cavadini E, Bettiga A, Prinetti A, Clagett-Dame M, Curley RW, Formelli F.
    Cancer Res; 2006 Mar 15; 66(6):3238-47. PubMed ID: 16540676
    [Abstract] [Full Text] [Related]

  • 16. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
    Raguénez G, Mühlethaler-Mottet A, Meier R, Duros C, Bénard J, Gross N.
    BMC Cancer; 2009 Mar 30; 9():97. PubMed ID: 19331667
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.
    Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG.
    Cancer Res; 1995 Feb 15; 55(4):853-61. PubMed ID: 7850799
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
    Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, Persiani S.
    Cancer Chemother Pharmacol; 2008 Sep 15; 62(4):655-65. PubMed ID: 18066548
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.